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ABSTRACT 21 
Renal calcium and phosphate handling is an important contributor to mineral homeostasis and bone 22 
health and the androgen receptor (AR) is highly expressed in the kidney. We investigated the short 23 
term effects of androgen deprivation on renal calcium and phosphate reabsorption, independent of 24 
their effects on bone. Two weeks following orchidectomy (ORX) of adult mice, bone loss occurred along 25 
with hypercalciuria, which was similarly prevented by testosterone and dihydrotestosterone 26 
supplementation. Treatment with bisphosphonates prior to ORX also inhibited hypercalciuria, 27 
indicating that the calcium flux originated from the bone. Renal calcium and phosphate transporter 28 
expression was increased post-ORX, independent of bisphosphonates. Furthermore, androgen 29 
deprivation appeared to stimulate local synthesis of 1,25(OH)2D3. When bisphosphonate-treated mice 30 
were fed a low calcium diet, bone resorption was no longer blocked and secondary 31 
hyperparathyroidism developed, which was more pronounced in ORX mice than sham-operated mice. 32 
In conclusion, this study shows that androgen deprivation increased renal calcium and phosphate 33 
transporter expression, independent of bone, and underlines the importance of adequate intestinal 34 
calcium supply in circumstances of androgen deprivation and bisphosphonate treatment. 35 




1. INTRODUCTION 38 
Recent studies suggested that sex steroids might play a role in the regulation of renal calcium and 39 
phosphate handling. Similar to calciophosphotropic hormones, sex hormones may not only influence 40 
calcium and phosphate handling in the bone but also in other organs such as the kidneys. Urinary 41 
calcium excretion has been shown to be higher in males than females, in both humans and mice (1,2). 42 
In addition, male mice exhibit lower expression levels of renal calcium transporters (2). In rats, 43 
orchidectomy (ORX) increased urinary calcium excretion, which was inhibited by testosterone (T) 44 
replacement (3). In contrast, decreased urinary calcium excretion was reported 2 weeks after ORX in 45 
mice, accompanied by an increased expression of renal calcium transporters (2). The available data on 46 
the effects of androgens on renal phosphate handling are limited and contradictory as well. Men 47 
treated with GnRH analogs exhibited increased serum phosphate levels as well as increased renal 48 
phosphate reabsorption (4,5). In contrast, ORX in male rats had no influence on serum phosphate or 49 
urinary phosphate excretion (6). Kidney stones, with hypercalciuria as major risk factor, are 2 to 3 times 50 
more frequent in males compared to females, and males with low T have lower odds of kidney stones 51 
(7,8). Mice lacking renal androgen receptor (AR) were shown to exhibit less calcium oxalate crystal 52 
formation (9).  53 
T is the main circulating androgen in men. It exerts its effects via the AR as T or, after conversion by 54 
the 5α-reductase, as dihydrotestosterone (DHT). In addition, T, but not DHT, can be aromatized into 55 
estradiol and bind to the estrogen receptor (ER). Hence, in tissues T can act via the AR as T or DHT, or 56 
via the ER as estradiol (10). In previous studies, we and others have shown that the well-established 57 
bone-sparing action of androgens is not entirely explained by direct effects on bone cells (11–14). 58 
Androgen action may at least partly be explained by its action on the kidneys. Renal AR expression is 59 
high, but the exact location of AR expression in the kidney is still debated, with expression reported 60 
along the entire nephron as well as in the glomerulus (15). The role of androgens, however, remains 61 
unresolved despite gender differences and hormonal dependence of typical kidney diseases such as 62 
nephrolithiasis, chronic kidney disease (incidence and progression) and predisposition for renal injury 63 
(16,17).  64 
Serum calcium and phosphate levels are tightly regulated between narrow ranges (15). The kidney but 65 
also the intestine and the bone represent exchange routes for calcium and phosphate. As such, the 66 
kidneys are major regulators of mineral homeostasis, as illustrated by the profound dysregulation of 67 
mineral metabolism during chronic kidney disease (18). Moreover, the role of the kidney becomes 68 
more dominant when intestinal calcium or phosphate absorption is suboptimal or when bone turnover 69 
is low (19,20). In the kidney, urinary calcium is mainly reabsorbed via passive paracellular transport in 70 
the proximal tubulus (PT) and the thick ascending limb of the loop of Henle (TAL), and partially by 71 
claudins which are epithelial tight junction proteins expressed along the entire nephron. Several 72 
claudins, including claudin-2, -12, -16 and -19, form channels to transport calcium from the tubular 73 
fluid into the circulation (21–24). The fine-tuning of renal calcium reabsorption, however, is believed 74 
to occur in the distal tubulus (DT) where calcium is taken up transcellularly via the transient receptor 75 
potential cation channel subfamily V member 5 (TRPV5) channel, transported by calbindin-D9K 76 
(CaBP9K) and calbindin-D28K (CaBP28K) to the basolateral membrane and exits the cell to the 77 
circulation via the sodium/calcium exchanger (NCX1) and plasma membrane calcium ATPase (PMCA) 78 
(25). The calcium-sensing receptor (CaSR) is expressed throughout the nephron with the highest 79 
expression in the TAL (26). When serum calcium increases, the CaSR will promote renal calcium 80 
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excretion through interaction with the claudin network and by altering potassium transport, hereby 81 
influencing the transepithelial potential difference and providing a driving force for the excretion of 82 
calcium (26,27). By contrast, urinary phosphate is reabsorbed mainly in the PT. Although much less is 83 
known about the transporters involved, several apical membrane phosphate transporters have been 84 
identified, including sodium-phosphate cotransporter 2c (NaPi-2c) and sodium-dependent phosphate 85 
transporter 1 and 2 (PiT1 and PiT2) (15).  86 
The kidney is also the main source of 1,25(OH)2D3 synthesis, which takes place in the PT. CYP27B1, 87 
predominantly expressed in the PT, is able to convert 25(OH)D3 to 1,25(OH)2D3. CYP24A1 limits the 88 
amount of 1,25(OH)2D3 when circulating 1,25(OH)2D3 is elevated by catalyzing the conversion of 89 
1,25(OH)2D3 into 24-hydroxylated products targeted for excretion or by producing 24,25(OH)2D3, thus 90 
decreasing the pool of 25(OH)D3 available for 1-hydroxylation. In the PT, VDR action mainly limits 91 
CYP27B1 activity, whereas in the DT it stimulates active transcellular calcium transport, in particular 92 
via CaBP9K/28K and to a lesser extent TRPV5 (25). 93 
In conclusion, current knowledge on the effects of androgens on renal calcium and phosphate handling 94 
is based on few and contradicting data. In addition, available findings could be confounded by effects 95 
of androgens on bone. Therefore, the aim of this study was to investigate the acute effects of androgen 96 
deprivation on renal calcium and phosphate handling in adult male mice, and this in the presence or 97 
absence of a bisphosphonate treatment. 98 
 99 
2. MATERIALS AND METHODS 100 
2.1.  Animals 101 
Male C57BL/6J mice (Charles River, Saint-Germain-Nuelles, France) were housed in a light and 102 
temperature-controlled room with ad libitum access to drinking water and standard chow (1% calcium, 103 
0.7% phosphate, Ssniff, Soest, Germany), unless stated otherwise. Nembutal (i.p. 100 mg/kg, Ceva 104 
Santé Animale, Libourne, France) followed by cardiac puncture was used for euthanasia. All animal 105 
procedures were approved by the KU Leuven animal ethics committee (P042/2014). For all 106 
experimental setups, male C57BL/6J mice were randomly allocated into different groups (n=12 per 107 
group) at 18 weeks of age to undergo a SHAM operation or a bilateral ORX under isoflurane anesthesia 108 
(3% induction, 2% maintenance), after 1 week of acclimatization. ORX was used as a model for primary, 109 
organic hypogonadism with acute and complete androgen deprivation (28). 110 
Experimental setup A (fig 1A): After the operation, implants of medical-grade silicone tubing (Silclear, 111 
Degania Medical, Degania, Israel) sealed with medical adhesive silicone (Silastic, Biesterfeld, Germany) 112 
were implanted in the nuchal region, either empty (vehicle, VEH) or filled with T or DHT (SHAM+VEH, 113 
ORX+VEH, ORX+T, ORX+DHT, n=12 per group). 114 
Experimental setup B (fig 1B): One week before the operation, mice were given vehicle (PBS, i.p., 115 
ThermoFisher Scientific, Massachusetts, USA) or risedronate injections (20 µg/kg, i.p., Merck, 116 
Darmstadt, Germany) every 4 days (SHAM+VEH, SHAM+RIS, ORX+VEH, ORX+RIS).  117 
Experimental setup C (fig 1C): One week before the operation, all mice started receiving risedronate 118 
injections every 4 days. Mice were also started on a normal calcium diet (NCD, 1%) or a low calcium 119 
diet (LCD, 0.02%) (SHAM+RIS+NCD, SHAM+RIS+LCD, ORX+RIS+NCD, ORX+RIS+LCD).  120 
4 
 
For all setups, 1 and 2 weeks after the operation, serum samples were taken via the submandibular 121 
vein and cardiac puncture respectively, and mice were put in metabolic cages for 24 h urine collections. 122 
Mice were euthanized and kidneys, femurs and vertebrae were taken out for further processing and 123 
analyses. 124 
2.2. Serum and urine analyses 125 
Calcium and phosphate levels in serum and urine were analyzed by SYNCHRON Clinical Systems 126 
(Beckman Coulter). Osteocalcin levels were assessed by radioimmunoassay as previously described 127 
(29). Serum 1,25(OH)2D3 was measured via LC-MS/MS. Serum PTH (Immutopics International, 128 
California, USA) and FGF23 (Kainos Laboratories Inc., Tokyo, Japan) levels were determined by ELISA. 129 
2.3. Gene expression analysis  130 
Total RNA of tissues was extracted with TRIzol (ThermoFisher Scientific) followed by 131 
phenol/chloroform purification. cDNA was synthesized using reverse transcriptase SuperScript II RT 132 
(ThermoFisher Scientific) and qRT-PCR was performed. Gene expression was normalized for 133 
hypoxanthine-guanine phosphoribosyltransferase (Hprt) and expressed relative to the control group 134 
(2 -ΔΔCT method). Details on the primers used are provided in supplementary table 1. A TaqMan assay 135 
for NaPi-2a was purchased from Thermofisher Scientific.  136 
2.4. Bone structure 137 
Micro-computed tomography (μCT) analysis of the L5 vertebrae was performed ex vivo using the high 138 
resolution SkyScan 1172 system (50 kV, 200 μA, 0.5 mm Al filter). Serial tomographs, reconstructed 139 
from raw data with the cone-beam reconstruction software (NRecon, V1.7.0.4; Skyscan), were used to 140 
compute trabecular parameters.  141 
2.5. Bone calcium content 142 
Femur dry weight was measured after overnight incubation at 100°C, followed by 8 hours at 500°C for 143 
ashing. Ashes were dissolved in 1M HCl and diluted 1/100 in water for calcium measurements with the 144 
SYNCHRON Clinical Systems (Beckman Coulter). Results were expressed relative to the dry weight and 145 
as total calcium weight. 146 
2.6. Immunohistochemistry 147 
Immunofluorescence co-stainings were carried out with antibodies directed against the AR and renal 148 
markers (podocin, megalin, uromodulin, trpv5) on kidneys of adult, male C57BL/6J mice. Antigen 149 
retrieval was performed in a 0.01M citrate solution using a pressure cooker. Antigen detection was 150 
performed using a Tyramide signal amplification (Perkin Elmer) system, followed by nuclear 151 
counterstaining with DAPI (4ʹ,6-diamidino-2-phenyl-indole dihydrochloride). Samples incubated 152 
without primary antibody were used as negative controls. Images were captured using a slide scanner 153 
microscope Axio Scan.Z1 (Zeiss). Details of antibodies and dilutions are provided in supplementary 154 
table 2. 155 
2.7. Statistical analyses 156 
Values are expressed as mean±SEM. Statistical significance between groups (p<0.05) was determined 157 
by One-Way (data from experimental setup A) or Two-Way (data from experimental setup B and C) 158 
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ANOVA, followed by Bonferroni’s test for multiple comparisons. All analyses were performed using 159 
GraphPad Prism (version 6.07, La Jolla California USA).  160 
 161 
RESULTS 162 
3.1. Androgen deprivation induces hypercalciuria and early bone loss  163 
In order to determine whether and how androgens influence renal calcium and phosphate handling, 164 
adult male mice were orchidectomized and treated with T, DHT, or vehicle (fig 1A). Serum and urinary 165 
calcium and phosphate levels after 1 and 2 weeks were compared with those of SHAM-operated mice 166 
treated with vehicle.  167 
Seminal vesicle weight, the most androgen-sensitive organ and measured to verify efficacy of ORX, 168 
was decreased 5 fold after ORX. Dietary calcium and phosphate intake was similar between the groups, 169 
as well as urinary volumes and renal function assessed by serum cystatin C levels (table 1). Serum 170 
calcium and phosphate levels were not different between ORX and SHAM mice (table 1). Urinary 171 
phosphate excretion was not affected either, while an increase in urinary calcium excretion was 172 
observed compared to SHAM (1.5 fold in week 1 and 2). This effect was abolished by both T or DHT 173 
replacement.  174 
Table 1. Effect of orchidectomy (ORX) on calcium and phosphate balance and general parameters 175 
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SHAM+VEH = sham-operated mice treated with vehicle; ORX+VEH = orchidectomized mice treated with vehicle; 177 
ORX+T = orchidectomized mice treated with T; ORX+DHT = orchidectomized mice treated with DHT; BW = body 178 
weight; ND = not done. 179 
Data are presented as mean ± SEM. One-Way ANOVA, n = 12 per group, a P<0.05 vs. SHAM+VEH; b P<0.05 vs. 180 
ORX+VEH. 181 
Since sex steroid deficiency induces early bone loss, which could interfere with the obtained results, 182 
trabecular bone was analyzed using microCT. Bone loss was observed already 2 weeks after ORX, as 183 
evidenced by a 15% decrease in bone mass with an 11% decrease in trabecular number, and a 4% 184 
increased trabecular separation. This bone loss was inhibited by T or DHT replacement (fig 2A). 185 
Increased bone turnover in ORX mice was confirmed by elevated serum osteocalcin levels (fig 2A). 186 
3.2. Bisphosphonates inhibit bone-loss induced calciuria in circumstances of sufficient dietary 187 
calcium 188 
As ORX induces early bone loss, mice were, prior to ORX or SHAM, treated with the bisphosphonate 189 
risedronate (versus vehicle) to inhibit bone resorption (fig 1B). MicroCT analysis confirmed that bone 190 
loss after ORX was prevented by risedronate (fig 2B). To confirm that the ORX-associated bone loss 191 
was induced by increased resorption and not by a mineralization defect, femurs were ashed and 192 
analyzed for calcium content. Calcium per dry weight was not affected by ORX, while total calcium 193 
levels decreased with 14%. This decrease was prevented by risedronate. Furthermore, risedronate 194 
prevented the increase of serum osteocalcin levels (fig 2B) and inhibited the ORX-induced 195 
hypercalciuria (fig 3A), indicating that the increased renal calcium loss originated from the bone. 196 
Phosphaturia remained unaffected.  197 
Regular chow for mice contains higher amounts of calcium than the recommended dietary intake. This 198 
high dietary calcium potentially affects renal calcium and phosphate handling. To minimize 199 
interference and study the effects of ORX independent of both bone and dietary calcium, mice were 200 
given either a normal calcium diet (NCD) or a low calcium diet (LCD). All the animals were SHAM or 201 
ORX-operated and treated with risedronate (fig 1C). MicroCT analysis showed that while risedronate 202 
efficiently inhibited ORX-induced bone loss under the regular diet, this was no longer the case under 203 
the LCD. The LCD decreased bone mass with 13% and 8% in SHAM and ORX mice, respectively (fig 2C). 204 
Femoral calcium/dry weight was not altered. LCD, however, did decrease total calcium levels with 15% 205 
in SHAM-operated mice and 14% in ORX mice (fig 2C). In addition, serum osteocalcin was significantly 206 
increased in ORX+RIS+LCD mice (fig 2C). Calciuria was not affected under LCD in circumstances of 207 
bisphosphonate treatment, but urinary phosphate excretion was 2.5 fold increased (fig 3B). The LCD 208 
did not influence intestinal calcium absorption, as assessed by 24h fecal calcium content corrected for 209 
dietary calcium intake (data not shown). 210 
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3.3. Androgen deprivation increases the expression of renal calcium and phosphate transporters   211 
Next, we investigated the effects of ORX on the expression of renal transporters involved in calcium 212 
and phosphate reabsorption after 2 weeks. As shown in figure 4A, renal mRNA expression of claudin-213 
2, -12, (located in the PT) -16 and -19 (located in the TAL) increased after ORX. The calcium transporters 214 
located in the DT (Trpv5, Cabp9k, Cabp28k, Ncx1 and Pmca) showed higher expression after ORX as 215 
well. Renal expression of CaSR was 2.1 fold increased in ORX mice. Also for the renal phosphate 216 
transporters NaPi-2c, Pit1 and Pit2 increased expression was observed, while NaPi-2a expression was 217 
not altered (fig 5A). Of note, although kidney weight decreased following ORX, relative cortical and 218 
medullary area was not different between SHAM and ORX mice (data not shown), thereby making it 219 
unlikely to affect the expression of these transporters. Following supplementation with T or DHT the 220 
increased expression of renal calcium and phosphate transporters was no longer observed.  221 
Following treatment with risedronate, enhanced expression of renal calcium transporters persisted. 222 
An additional increase was even observed for the DT-related renal calcium transporters Trpv5, Cabp9k, 223 
and Cabp28k after ORX (fig 4B). CaSR expression was lower in risedronate-treated versus vehicle-224 
treated ORX mice. Expression of renal claudins (fig 4B) and phosphate transporters (fig 5B) was 225 
similarly increased in vehicle-treated and risedronate-treated mice. 226 
Finally, the LCD induced an additional increase in the calcium transporters claudin-19, Trpv5, Cabp9k, 227 
and Pmca in ORX mice (fig 4C). The diet had no effect on CaSR or phosphate transporter expression 228 
(fig 5C). 229 
3.4. The renal androgen receptor expression is mainly located in the proximal tubulus 230 
To understand androgen-AR action in the kidney, including renal calcium and phosphate handling, it is 231 
essential to know where the AR is expressed. We performed immunofluorescence co-stainings for the 232 
AR with specific markers of different renal substructures. As shown in figure 6, the AR is located 233 
predominantly in the PT (nuclear expression, whereas megalin is located at the apical border), without 234 
expression in the TAL or DT. 235 
3.5. Androgen deprivation increases renal vitamin D metabolism 236 
ORX increased renal mRNA expression of the vitamin D receptor (Vdr), as well as Cyp27b1 and Cyp24a1 237 
(fig 7A). This increase was absent in case of T or DHT supplementation. When mice were treated with 238 
risedronate, an additional increase in Cyp27b1 expression was observed after ORX (fig 7B). Finally, in 239 
circumstances of low dietary calcium a 10 fold increased expression of Cyp27b1 was observed in the 240 
ORX+LCD group compared to the control group (fig 7C). Serum analyses indicated secondary 241 
hyperparathyroidism under the low calcium diet, with increased PTH and 1,25(OH)2D3 levels, most 242 
pronounced for the ORX mice (fig 8B).  243 
 244 
3. DISCUSSION 245 
We show that androgen deprivation by orchidectomy in adult mice acutely increased the expression 246 
of renal calcium and phosphate transporters and local vitamin D metabolism independent of bone in 247 
cicumstances of sufficient dietary calcium intake.   248 
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The observation of increased calciuria post-ORX is in agreement with other studies (3,6). Hsu et al. 249 
however reported  reduced urinary calcium excretion in mice 2 weeks post-ORX, assuming that this 250 
was a too short period to cause significant bone changes (2). Yet we show significant bone loss by 251 
microCT, calcium content in ashed bone and increased serum bone turnover markers. The finding of 252 
early bone loss following ORX, due to a well-established imbalance between bone resorption and 253 
formation, is in line with previous findings of our group (30). In order to circumvent this potentially 254 
confounding  impact on bone homeostasis in the study of renal effects of androgen modulation, we 255 
suppressed bone resorption with a bisphosphonate prior to ORX and showed that hypercalciuria was 256 
prevented, indicating that the calcium flux originated from the bone.  257 
Dietary calcium intake in mice is high due to regular mouse chow containing high calcium levels (31), 258 
which contrasts with the often low dietary calcium intake in – especially elderly and frail- humans. 259 
Hence, we investigated whether the changes we observed could be confirmed in circumstances of low 260 
dietary calcium intake. Surprisingly, the combination of bisphosphonate treatment and very low 261 
calcium diet did not decrease serum or urinary calcium levels after ORX, while phosphaturia increased. 262 
However, when mice were fed a low calcium diet, bisphosphonate treatment was no longer able to 263 
fully block bone resorption. Most likely this was due to the secondary hyperparathyroidism, as shown 264 
by high serum levels of PTH and 1,25(OH)2D3. This calciotropic response was particularly pronounced 265 
in ORX mice and reflected by the high phosphaturia as well. These acute changes probably reflect a 266 
compensatory renal action to maintain serum calcium and phosphate levels in circumstances of 267 
androgen deprivation. This finding is clinically relevant, as men treated with androgen deprivation 268 
therapy and at increased risk for secondary osteoporosis often have a low dietary calcium and vitamin 269 
D intake (32–34). Treatment with bisphosphonates might thus be less effective under circumstances 270 
of combined hypogonadism and low dietary calcium (35). Very few data are available with respect to 271 
the effects of androgens on renal phosphate handling. Similar to our study, serum and urinary 272 
phosphate levels were unaffected in male rats, 3 months after ORX (6). 273 
Expression of renal calcium and phosphate transporters, involved in both paracellular and transcellular 274 
reabsorption along the nephron, was increased after androgen deprivation. This finding persisted after 275 
inhibition of bone resorption by bisphosphonate treatment, indicating that the effects on the renal 276 
calcium and phosphate transporter expression are independent of the effects on bone. The calcium 277 
transporters that are expressed at the level of the DT even exhibited an additional increase after 278 
bisphosphonate treatment. This does not appear to be a direct effect on transporter expression, as 279 
risedronate did not alter expression in sham-operated mice. The increased expression of renal CaSR, 280 
promoting calciuria, after ORX could be secondary to the calcium flux from bone to serum thereby 281 
preventing transient hypercalcemia. This is supported by the finding of decreased CaSR expression 282 
after bisphosphonate treatment. T or DHT suppressed calcium and phosphate transporter expression 283 
to a similar extent, suggesting that androgens inhibit renal calcium and phosphate transporters 284 
exclusively via the AR. Similar to our experiments, others showed increased expression of renal DT 285 
calcium transporters following ORX in mice as well (2). To our knowledge, no other data are available 286 
on the effects of androgens on renal PT phosphate transporters. Mice fed a low calcium diet exhibited 287 
a further increase of renal calcium transporters Cldn19, Trpv5, Cabp9k and Pmca. CaSR expression 288 
remained elevated as well, probably explaining the absence of expected hypocalcuria which is usually 289 
observed in circumstances of low intestinal calcium supply. The physiological role of the increase in 290 
renal calcium and phosphate transporters, including CaSR, shortly after androgen deprivation is 291 
unclear. In order to investigate the role of the renal AR in renal calcium and phosphate handling, and 292 
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whether the absence of renal AR in its turn influences bone, the development of a mouse model with 293 
kidney-specific knockout of the AR would be desirable. 294 
The mechanism of the unexpected androgen/AR-mediated modulation of calcium and phosphate 295 
transporters in different parts of the nephron remains speculative. Renal 1,25(OH)2D3/VDR action, 296 
however, might mediate the increased calcium and phosphate transporter expression during androgen 297 
deprivation. First, we observed increased renal expression of markers of vitamin D metabolism post-298 
ORX, independent of bisphosphonate treatment. Our data regarding vitamin D metabolism are in line 299 
with renal transcriptome analyses, showing reduced Cyp24a1 mRNA 12 hours after T treatment of ORX 300 
male mice. Cyp27b1 was also decreased after 3 days of T treatment (36). Second, we have shown that 301 
the AR is dominantly expressed in the PT, where 25(OH)D3 is taken up by endocytosis and where the 302 
synthesis of 1,25(OH)2D3 takes place (25). Third, renal VDR action is also known to be present in the DT 303 
where it regulates active transcellular calcium transport. We have shown that the vitamin D-regulated 304 
calcium transporters Trpv5, Cabp9k, and Cabp28k were increased in ORX mice, independent of 305 
bisphosphonate treatment. Thus, increased synthesis of 1,25(OH)2D3 in circumstances of low 306 
androgens at the level of the PT could increase active phosphate reabsorption at the level of the PT 307 
but also active calcium reabsorption at the level of the DT.  308 
Our study underlines the complex and dynamic interplay between the kidney, bone and intestines with 309 
respect to calcium and phosphate homeostasis. In contrast to other studies, our experimental setup 310 
took into account the confounding effect of early bone loss by androgen deprivation as well as the role 311 
of the dietary calcium content. Similar to earlier studies, androgen deprivation induced an increase of 312 
major renal calcium transporters in the DT, mediated via the AR and persisting after modulation of 313 
bone resorption and calcium intake. Moreover, as schematically summarized in figure 9, we extended 314 
this observation to more renal (transcellular as well as paracellular) calcium and phosphate 315 
transporters which are also expressed in the PT, which appears to be the primary target site of 316 
androgens with dominant localization of the AR. As androgens decrease renal calcium and phosphate 317 
transporter expression, it is unlikely that the kidney plays a role in the bone-sparing effect of 318 
androgens. However, the overall striking impact of androgens on renal calcium and phosphate 319 
transporters appears to be a highly conserved AR-dependent effect, which may play a role in the 320 
pathophysiology of kidney diseases with a sex (hormone) difference in prevalence, such as 321 
nephrolithiasis and chronic kidney disease. The main limitation of this study is the lack of a mechanistic 322 
pathway. We explored short-term effects of androgen deprivation in mice with a normal kidney 323 
function. Future studies with long-term androgen deprivation and with models of nephrolithiasis and 324 
renal insufficiency are of course of high interest.  325 
In conclusion, this study shows that androgens modulate renal calcium and phospate transporters via 326 
the AR and independent from bone. This effect on the kidney is probably not clinically relevant in 327 
hypogonadal osteoporosis but could play a role in prevalent kidney diseases. Finally, we show that 328 
adequate intestinal calcium supply is pivotal in combined circumstances of androgen deprivation and 329 
bisphosphonate treatment.  330 
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Figure 1. Schematic overview of the experimental setups. A. Orchidectomy (ORX) and androgen 437 
replacement (T or DHT) B. ORX preceded by bisphosphonate (risedronate) treatment C. ORX preceded 438 
by bisphosphonate treatment and low calcium diet. Asterixes indicate the timing of metabolic cage 439 
housing for 24-hour urine collections and blood sampling. 440 







Figure 2. Early effects of androgen deprivation on bone. A. Effect of orchidectomy (ORX) and 443 
androgen replacement on trabecular bone parameters in the L5 vertebrae (top), 3D reconstructions of 444 
the vertebral body and  serum osteocalcin (bottom) B. Effect of ORX and risedronate on trabecular 445 
bone parameters in the L5 vertebrae (top), femoral calcium content and serum osteocalcin (bottom) 446 
C. Effect of ORX, risedronate, and dietary calcium on trabecular bone parameters in the L5 vertebrae 447 
(top), femoral calcium content and serum osteocalcin (bottom). BV/TV = bone mass; Tb. N = trabecular 448 
number; Tb. Sp = trabecular separation. SHAM+VEH: sham-operated mice treated with vehicle; 449 
ORX+VEH: orchidectomized mice treated with vehicle; ORX+T: orchidectomized mice treated with T; 450 
ORX+DHT: orchidectomized mice treated with DHT. VEH: vehicle; RIS: risedronate; NCD: normal 451 
calcium diet; LCD: low calcium diet. Data are presented as mean ± SEM. One-Way ANOVA (A) and Two-452 
Way ANOVA (B-C) with Bonferroni’s test for multiple comparisons, n = 12 per group. 453 







Figure 3. Effects of bisphosphonate treatment and low dietary calcium on urinary calcium and 455 
phosphate excretion after androgen deprivation. A. Effect of orchidectomy (ORX) and risedronate B. 456 
Effect of ORX, risedronate, and dietary calcium. SHAM+VEH: sham-operated mice treated with vehicle; 457 
SHAM+RIS: sham-operated mice treated with risedronate; ORX+VEH: orchidectomized mice treated 458 
with vehicle; ORX+RIS: orchidectomized mice treated with risedronate. SHAM+RIS+NCD: sham-459 
operated mice treated with risedronate and fed a normal calcium diet; SHAM+RIS+LCD: sham-460 
operated mice treated with risedronate and fed a low calcium diet; ORX+RIS+NCD: orchidectomized 461 
mice treated with risedronate and fed a normal calcium diet; ORX+RIS+LCD: orchidectomized mice 462 
treated with risedronate and fed a low calcium diet. Data are presented as mean ± SEM. Two-Way 463 
ANOVA with Bonferroni’s test for multiple comparisons, n = 12 per group. 464 






Figure 4. Effects of androgen deprivation on renal mRNA expression of calcium transporters. A. Effect 467 
of orchidectomy (ORX) and androgen replacement B. Effect of ORX and risedronate C. Effect of ORX, 468 
risedronate, and dietary calcium. SHAM+VEH: sham-operated mice treated with vehicle; ORX+VEH: 469 






orchidectomized mice treated with DHT; SHAM+RIS: sham-operated mice treated with risedronate; 471 
ORX+RIS: orchidectomized mice treated with risedronate; SHAM+RIS+NCD: sham-operated mice 472 
treated with risedronate and fed a normal calcium diet; SHAM+RIS+LCD: sham-operated mice treated 473 
with risedronate and fed a low calcium diet; ORX+RIS+NCD: orchidectomized mice treated with 474 
risedronate and fed a normal calcium diet; ORX+RIS+LCD: orchidectomized mice treated with 475 
risedronate and fed a low calcium diet. Data are presented as mean ± SEM. One-Way ANOVA (A) and 476 
Two-Way ANOVA (B-C) with Bonferroni’s test for multiple comparisons, n = 12 per group. 477 





Figure 5. Effects of androgen deprivation on renal mRNA expression of phosphate transporters. A. 481 
Effect of orchidectomy (ORX) and androgen replacement B. Effect of ORX and risedronate C. Effect of 482 
ORX, risedronate, and dietary calcium. SHAM+VEH: sham-operated mice treated with vehicle; 483 
ORX+VEH: orchidectomized mice treated with vehicle; ORX+T: orchidectomized mice treated with T; 484 
ORX+DHT: orchidectomized mice treated with DHT; SHAM+RIS: sham-operated mice treated with 485 
risedronate; ORX+RIS: orchidectomized mice treated with risedronate; SHAM+RIS+NCD: sham-486 
operated mice treated with risedronate and fed a normal calcium diet; SHAM+RIS+LCD: sham-487 
operated mice treated with risedronate and fed a low calcium diet; ORX+RIS+NCD: orchidectomized 488 
mice treated with risedronate and fed a normal calcium diet; ORX+RIS+LCD: orchidectomized mice 489 
treated with risedronate and fed a low calcium diet. Data are presented as mean ± SEM. One-Way 490 
ANOVA (A) and Two-Way ANOVA (B-C) with Bonferroni’s test for multiple comparisons, n = 12 per 491 
group. 492 





















Figure 6. AR localization in the kidney. Immunofluorescence co-stainings of the AR (red) and different 495 
kidney markers (green), with nuclei in blue. Markers from top to bottom: podocin (glomerulus); 496 
megalin (PT); uromodulin (TAL); Trpv5 (DT). Scale bar = 50 µm. 497 
 498 
Figure 7. Effects of androgen deprivation on renal mRNA expression of markers of vitamin D 499 
metabolism. A. Effect of orchidectomy (ORX) and androgen replacement B. Effect of ORX and 500 
risedronate C. Effect of ORX, risedronate, and dietary calcium. SHAM+VEH: sham-operated mice 501 
treated with vehicle; ORX+VEH: orchidectomized mice treated with vehicle; ORX+T: orchidectomized 502 
mice treated with T; ORX+DHT: orchidectomized mice treated with DHT; SHAM+RIS: sham-operated 503 
mice treated with risedronate; ORX+RIS: orchidectomized mice treated with risedronate; 504 
SHAM+RIS+NCD: sham-operated mice treated with risedronate and fed a normal calcium diet; 505 
SHAM+RIS+LCD: sham-operated mice treated with risedronate and fed a low calcium diet; 506 
ORX+RIS+NCD: orchidectomized mice treated with risedronate and fed a normal calcium diet; 507 






presented as mean ± SEM. One-Way ANOVA (A) and Two-Way ANOVA (B-C) with Bonferroni’s test for 509 
multiple comparisons, n = 12 per group. 510 





Figure 8. Effect of low calcium diet on calciophosphotropic hormones. A. Serum PTH B. Serum 514 
1,25(OH)2D3. SHAM+RIS+NCD: sham-operated mice treated with risedronate and fed a normal calcium 515 
diet; SHAM+RIS+LCD: sham-operated mice treated with risedronate and fed a low calcium diet; 516 
ORX+RIS+NCD: orchidectomized mice treated with risedronate and fed a normal calcium diet; 517 
ORX+RIS+LCD: orchidectomized mice treated with risedronate and fed a low calcium diet. Data are 518 
presented as mean ± SEM. Two-Way ANOVA with Bonferroni’s test for multiple comparisons, n = 12 519 
per group. 520 






Figure 9. Summary of the effects of short term androgen deprivation on renal calcium and phosphate 524 
handling in adult male mice. ORX (black arrows) induced hypercalciuria and increased expression of 525 
renal calcium and phosphate transporters, which was inhibited by T and DHT replacement (blue) to a 526 
similar extent, indicative for an AR-mediated effect. Treatment with bisphosphonates (green) prior to 527 
ORX prevented hypercalciuria, confirming bone as the origin for the urinary calcium loss. However, 528 
increased expression of renal calcium and phosphate transporters persisted or even increased, 529 
indicating bone-independent effects. In bisphosphonate-treated orchidectomized mice fed a low 530 
calcium diet (red), an additional increase in distal renal calcium transporters was seen which was 531 
accompanied by secondary hyperparathyroidism, most probably explaining the pronounced 532 
hyperphosphaturia. 533 






















SUPPLEMENTAL DATA 535 
Supplementary table 1. Primers used for gene expression analysis 536 
Hprt Forward TTATCAGACTGAAGAGCTACTGTAATGATC 
 Reverse TTACCAGTGTCAATTATATCTTCAACAATC 
 Probe TGAGAGATCATCTCCACCAATAACTTTTATGTCCC 
Trpv5 Forward CGTTGGTTCTTACGGGTTGAAC 
 Reverse GTTTGGAGAACCACAGAGCCTCTA 
 Probe TGTTTCTCAGATAGCTGCTCTTGTACTTCCTCTTTGT 
Cabp9k Forward CCTGCAGAAATGAAGAGCATTTT 
 Reverse CTCCATCGCCATTCTTATCCA 
 Probe CAAAAATATGCAGCCAAGGAAGGCGA 
Cabp28k Forward AACTGACAGAGATGGCCAGGTTA 
 Reverse TGAACTCTTTCCCACACATTTTGAT 
 Probe ACCAGTGCAGGAAAATTTCCTTCTTAAATTCCA 
Ncx1 Forward TCCCTACAAAACTATTGAAGGCACA 
 Reverse TTTCTCATACTCCTCGTCATCGATT 
 Probe ACCTTGACTGATATTGTTTTGACTATTTCATCATTCTGGA 
Pmca Forward CGCCATCTTCTGCACCATT 
 Reverse CAGCCATTGCTCTATTGAAAGTTC 
 Probe CAGCTGAAAGGCTTCCCGCCAAA 
Cldn2 Forward GCTGCCCAGGCCATGAT 
 Reverse GCTCGAGAATCCTGGCAGAA 
 Probe TGCATCTCATGCCCACCACAGAGATAAT 
Cldn12 Forward GCAGTGACTGCCTGATGTACGA 
 Reverse ACATTCCAATCAGGCAGAGTAGC 
 Probe CCTGCGTGTCCTCCAGTTTGCCC 
Cldn16 Forward CCATGTGTCCCTTCCCAACA 
 Reverse GTGGCCACGATCAAAAACCC 
Cldn19 Forward ACTGCTGCCAGAGAACCTGT 
 Reverse AACCCTGGCCTTTACACACC 
Napi-2c Forward CAG GAA TCT CCG GTT CCA TTC 
 Reverse TCA GTT GGT CAG CGT TCT TC 
Pit1 Forward GCTGCTTCACGAGTGGGTAG 
 Reverse ACGCAAGTTCATCCAAAGGAA 
Pit2 Forward GATTGTCGCCTCCTGGTTTAT 
 Reverse GGAACAGGGTCCTCCTTAGTA 
Vdr Forward CAGCACATTATCGCCATCCT 
 Reverse GGTTCCATCATGTCCAGTGAG 
Cyp24a1 Forward CCATTCACAACTCGGACCCT 
 Reverse AAGACTGTTCCTTTGGGTAGC 
Cyp27b1 Forward CCAATATGGTCTGGCAGCTTT 
 Reverse CATTCTTCACCATCCGCCGTTA 
  537 
25 
 




Protein Antibody Dilution 
AR Spring Bioscience M4070 1/3000 
Podocin Abcam ab93650 1/2000 
Megalin Santa Cruz Biotechnology sc-515750 1/3000 
Uromodulin R&D systems MAB5175 1/3000 
Trpv5 Novus Biologicals NB100-93520 1/2000 
